Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. Ichikawa W, et al. Among authors: tanaka c. Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16. Br J Cancer. 2015. PMID: 25880011 Free PMC article.
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Nakayama G, Tanaka C, Uehara K, Mashita N, Hayashi N, Kobayashi D, Kanda M, Yamada S, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Ando Y, Kodera Y. Nakayama G, et al. Among authors: tanaka c. Cancer Chemother Pharmacol. 2014 Apr;73(4):847-55. doi: 10.1007/s00280-014-2416-x. Epub 2014 Feb 28. Cancer Chemother Pharmacol. 2014. PMID: 24577566 Clinical Trial.
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. Nakayama G, et al. Among authors: tanaka c. BMC Cancer. 2017 Apr 4;17(1):243. doi: 10.1186/s12885-017-3245-1. BMC Cancer. 2017. PMID: 28376737 Free PMC article. Clinical Trial.
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G, Mitsuma A, Sunagawa Y, Ishigure K, Yokoyama H, Matsui T, Nakayama H, Nakata K, Ishiyama A, Asada T, Umeda S, Ezaka K, Hattori N, Takami H, Kobayashi D, Tanaka C, Kanda M, Yamada S, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. Nakayama G, et al. Among authors: tanaka c. Oncologist. 2018 Aug;23(8):919-927. doi: 10.1634/theoncologist.2017-0640. Epub 2018 Jul 26. Oncologist. 2018. PMID: 30049885 Free PMC article. Clinical Trial.
Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).
Hattori N, Nakayama G, Uehara K, Aiba T, Ishigure K, Sakamoto E, Tojima Y, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Nagino M, Kodera Y. Hattori N, et al. Among authors: tanaka c. Int J Clin Oncol. 2020 Jan;25(1):118-125. doi: 10.1007/s10147-019-01546-3. Epub 2019 Sep 21. Int J Clin Oncol. 2020. PMID: 31542847 Free PMC article. Clinical Trial.
Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
Nakayama G, Takano N, Taniguchi H, Ishigure K, Yokoyama H, Teramoto H, Hashimoto R, Sakai M, Ishiyama A, Kinoshita T, Hayashi N, Nakamura M, Hattori N, Sato Y, Umeda S, Uehara K, Aiba T, Sonohara F, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Murotani K, Ando M, Ando Y, Muro K, Kodera Y. Nakayama G, et al. Among authors: tanaka c. Eur J Cancer. 2021 Feb;144:61-71. doi: 10.1016/j.ejca.2020.11.007. Epub 2020 Dec 16. Eur J Cancer. 2021. PMID: 33340853 Clinical Trial.
Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53-Bcl-2 intrinsic apoptosis pathway.
Miwa T, Kanda M, Shimizu D, Umeda S, Sawaki K, Tanaka H, Tanaka C, Hattori N, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y. Miwa T, et al. Among authors: tanaka c, tanaka h. Br J Cancer. 2021 Apr;124(8):1449-1460. doi: 10.1038/s41416-021-01271-7. Epub 2021 Feb 3. Br J Cancer. 2021. PMID: 33531692 Free PMC article.
S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
Watanabe J, Sasaki S, Kusumoto T, Sakamoto Y, Yoshida K, Tomita N, Maeda A, Teshima J, Yokota M, Tanaka C, Yamauchi J, Uetake H, Itabashi M, Takahashi K, Baba H, Kotake K, Boku N, Aiba K, Morita S, Takenaka N, Sugihara K. Watanabe J, et al. Among authors: tanaka c. ESMO Open. 2021 Apr;6(2):100077. doi: 10.1016/j.esmoop.2021.100077. Epub 2021 Mar 11. ESMO Open. 2021. PMID: 33714860 Free PMC article. Clinical Trial.
1,482 results